EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database

Yang Rui, Tianyuan Xin, Yu Chen, Beiyi Xiang, Changwen Chen, Lin Zhang, Zhe Chen

Journal of Pharmacy & Pharmaceutical Sciences · 2025

DOI: 10.3389/jpps.2025.14917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2025. Verfasst von Yang Rui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China. Hauptthemen laut MEDLINE: Tiotropium Bromide, Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Bronchodilator Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tiotropium, a long-acting muscarinic antagonist, is commonly employed for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. While its efficacy has been validated through numerous randomized controlled trials, safety concerns in real-world post-marketing settings necessitate further evaluation.

Aim

This study aimed to analyze the adverse events (AEs) associated with tiotropium reported in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database to identify potential safety signals.

Methods

A retrospective analysis was conducted on adverse reaction reports related to tiotropium in the FAERS database from the first quarter of 2004 to the fourth quarter of 2024. The AE names in the FAERS database were systematically classified using the Preferred Terms (PTs) and System Organ Classes (SOCs) provided by the latest version of the Medical Dictionary for Regulatory Activities (MedDRA 27.1). After deduplication, a combination of methods, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS), was employed for disproportionality analysis.

Results

A total of 129,763 AE reports related to tiotropium were included in the analysis, affecting 65,045 patients. These reports encompassed 27 different SOC categories, identifying 264 AEs associated with tiotropium. After excluding certain AEs deemed clinically insignificant, the most common AEs reported were dyspnea (n = 8,600), cough (n = 2,440), and pneumonia (n = 2080). The AEs exhibiting the highest signal strength included aggravated dyspnea (ROR: 162.04), hoarseness (ROR: 43.42), and aggravated chronic obstructive airway disease (ROR: 43.17). Additionally, we identified potential risks not mentioned in the instructions (United States Prescribing Information and the Canadian Product Monograph), such as epiglottic cancer, halo vision, and malignant lung tumors.

Conclusion

This study offers a more comprehensive understanding of tiotropium by uncovering previously unreported adverse reactions. Physicians should take these newly identified adverse reactions into account when prescribing this medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tiotropium BromidePharmacovigilanceAdverse Drug Reaction Reporting SystemsBronchodilator AgentsDrug-Related Side Effects and Adverse ReactionsHumansUnited StatesUnited States Food and Drug AdministrationRetrospective StudiesDatabases, FactualMaleFemaleMiddle AgedAgedAdultPulmonary Disease, Chronic Obstructive

Stichwörter der Autor:innen

adverse drug eventsdata miningdisproportionality analysispharmacovigilancetiotropium

Substanzen

Tiotropium BromideBronchodilator Agents

Autor:innen und Institutionen

  • Laboratory of Cough, Kunshan Key Laboratory of Chronic Cough, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.
  • Department of Oncology, Changshu No.1 People's Hospital, Changshu Hospital Affiliated to Soochow University, Suzhou, China.

Zitieren

APA

Rui, Y., Xin, T., Chen, Y., Xiang, B., Chen, C., Zhang, L., & Chen, Z. (2025). Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2025.14917

Vancouver

Rui Y, Xin T, Chen Y, Xiang B, Chen C, Zhang L, et al. Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database. Journal of Pharmacy & Pharmaceutical Sciences. 2025. doi:10.3389/jpps.2025.14917

BibTeX
@article{Rui2025,
  author = {Rui, Yang and Xin, Tianyuan and Chen, Yu and Xiang, Beiyi and Chen, Changwen and Zhang, Lin and Chen, Zhe},
  title = {Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2025},
  doi = {10.3389/jpps.2025.14917}
}
Kostenlos starten →